InMed Pharmaceuticals Inc.
INM
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 820.20K | 1.12M | 1.30M | 1.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 820.20K | 1.12M | 1.30M | 1.26M |
| Cost of Revenue | -- | 636.00K | 717.00K | 728.10K | -- |
| Gross Profit | -- | 184.20K | 403.20K | 576.70K | -- |
| SG&A Expenses | 1.74M | 1.62M | 1.53M | 2.25M | 1.58M |
| Depreciation & Amortization | 51.70K | 53.20K | 53.20K | 52.80K | 51.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.82M | 2.94M | 2.88M | 3.15M | 2.06M |
| Operating Income | -2.82M | -2.12M | -1.76M | -1.84M | -2.06M |
| Income Before Tax | -2.79M | -2.03M | -1.73M | -1.79M | -2.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.79M | -2.03M | -1.73M | -1.79M | -2.07M |
| Earnings from Discontinued Operations | -174.60K | -- | -- | -- | -53.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.97M | -2.03M | -1.73M | -1.79M | -2.12M |
| EBIT | -2.82M | -2.12M | -1.76M | -1.84M | -2.06M |
| EBITDA | -2.77M | -2.07M | -1.71M | -1.79M | -2.01M |
| EPS Basic | -0.73 | -0.51 | -0.44 | -1.20 | -1.94 |
| Normalized Basic EPS | -0.43 | -0.32 | -0.27 | -0.75 | -1.18 |
| EPS Diluted | -0.73 | -0.51 | -0.44 | -1.20 | -1.94 |
| Normalized Diluted EPS | -0.43 | -0.32 | -0.27 | -0.75 | -1.18 |
| Average Basic Shares Outstanding | 4.05M | 3.95M | 3.95M | 1.49M | 1.10M |
| Average Diluted Shares Outstanding | 4.05M | 3.95M | 3.95M | 1.49M | 1.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |